New Dual-Action antibody takes on advanced cancers

NCT ID NCT04606472

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm gastric adenocarcinoma gastroesophageal junction adenocarcinoma malignant mesothelioma melanoma neoplasm non-small cell lung carcinoma renal cell carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital

Wuhan, Hubei, China
Shanghai Central Hospital

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China
Union Hospital Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
West China Hospital, Sichuan University

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.